GT Biopharma Inc GTBP 深 沪
交易中 08-17 12:09:33 美东时间
0.2877
-0.008
-2.80%
华盛通- 最 高0.2929
- 今 开0.29
- 成交量 29.32万股
- 最 低 0.2814
- 昨 收 0.296
- 总市值 1275.62万
- 52周最高 1.37
- 市盈率 静 --
- 换手率 0.66%
- 52周最低 0.261
- 委 比 11.11%
- 总股本 4433.86万
- 历史最高 591.99
- 量 比 1.59
- 振 幅 3.89%
- 历史最低 0.261
- 每 手 1
- 风险率 0.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GT Biopharma Q2 EPS $(0.12) Misses $(0.08) Estimate
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.08) by 50 percent. This is a 78.18 percent increase over losses of $(0.55) per share from the same period last year.
08-14 20:29
GT Biopharma reports Q2 results
GT Biopharma press release (GTBP): Q2 net loss for the second quarter of 2026 of approximately $4.5 million, compared to $30.2 million for the same comparable quarter of 2025. The Company had cash and...
08-14 20:10
GT Biopharma Reports Second Quarter 2026 Financial Results
GT Biopharma reported second quarter 2026 financial results with a cash balance of $5.1 million, sufficient to fund operations through Q4 2026. The company has two TriKE® candidates in Phase 1 trials: GTB-3650 for CD33-positive leukemias and GTB-5550 for B7-H3-positive solid tumors, with updates expected in late 2026. GTB-5550 features subcutaneous dosing. Increased AI integration aims to advance multiple new candidates toward pre-IND development...
08-14 12:00
GT Biopharma Lowers Stockholder Quorum to One-Third
GT Biopharma ( ($GTBP) ) has provided an announcement. On June 8, 2026, GT Biop...
06-13 07:02
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout
GT Biopharma says AI-driven drug discovery tools are accelerating pipeline development and may yield new pre-IND candidates by 2027.
06-01 19:31
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
GT Biopharma is leveraging AI-based tools to accelerate the development of tumor-targeting engagers and multi-domain proteins, reducing costs and reliance on trial-and-error experimentation. These technologies enhance binding, stability, and functional activity, shortening timelines and increasing the likelihood of translational success. The company expects multiple new development candidates to enter pre-IND development in 2027, with potential a...
06-01 12:00
Nasdaq Grants GT Biopharma Additional 180 Days To Regain Compliance
https://www.sec.gov/ix?doc=/Archives/edgar/data/109657/000149315226024913/form8-k.htm
05-22 20:11
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
Issued on behalf of GT Biopharma, Inc. SAN FRANCISCO, May 18, 2026 /PRNewswire/ -- USA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically pe...
05-19 02:22
GT Biopharma Q1 EPS $(0.11) Misses $(0.08) Estimate
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 66.67 percent increase over losses of $(0.33) per share from the
05-15 20:19
GT Biopharma Reports First Quarter 2026 Financial Results
GT Biopharma announced its Q1 2026 financial results, highlighting $9 million in cash and ongoing Phase 1 trials for GTB-3650 and GTB-5550. GTB-3650 targets CD33-positive leukemias, with enrollment progressing through dose escalation cohorts. GTB-5550, the first subcutaneously administered TriKE, focuses on B7-H3-positive solid tumors, with enrollment ongoing across multiple tumor types. The company expects updates on both programs in H2 2026. GT...
05-15 12:00
